tbuckley/cabot-search huggingface dataset:
Complementary and alternative medicine (CAM) use among cancer patients in community oncology settings.
Authors: P. A. Parker, L. Cohen, B. N. Bekele, H. Hough, R. T. Lee, M. Fisch
Journal: Journal of Clinical Oncology (2010)

e19544 Background: Previous surveys of CAM use in oncology have primarily been conducted at comprehensive cancer centers and other major medical centers. The prevalence and attitudes towards CAM in community oncology settings is unknown. Methods: We are conducting an educational intervention within the M. D. Anderson CCOP network to encourage oncology nurses to discuss CAM use with their patients. Here we provide baseline data on the frequency of and reasons for CAM use and how often CAM was discussed with oncology health care practitioners. Participants included 566 cancer patients from 36 CCOP component sites. Questionnaires were completed immediately following the patient's oncology visit. Results: Patients were 65% female, 86% non-Hispanic white, average age of 59 (range 23-88), and 30% had a college degree or higher. The most common cancers were breast cancer (31%), lung cancer (12%), and colorectal cancer (10%). Time since initial cancer diagnosis was 1.96 years and 28% had a cancer recurrence. Thirty-nine percent indicated that they have used one or more CAM therapies following their cancer diagnosis. Reasons for using CAM included: believes CAM beneficial (27%), to address the emotional and spiritual aspects of the disease (23%), and to boost immune system (21%). The most common categories of CAM used by patients were massage therapy (19%), relaxation techniques (19%), special diet (18%) and megavitamins (15%). Patients indicated that 9% of their physicians and 12% of nurses had asked them about their use of CAM at that oncology visit. Twenty-one percent of patients reported that they initiated a discussion with their providers about their use of CAM and the most common responses were: encouraged me to continue (13%) and was neutral (7%). Reasons for not telling health care practitioners about CAM use included: my health care provider never asked (27%) and unsure if CAM beneficial (18%). Conclusions: More than one-third of patients indicated that they used some type of CAM therapy and the majority of their providers did not ask them about their CAM use. There remains considerable uncertainty among patients about the role of CAM in the context of cancer care. No significant financial relationships to disclose.
Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals
Authors: F. Buonfiglioli, F. Conti, P. Andreone, C. Crespi, F.G. Foschi, M. Lenzi, G. Mazzella, G. Verucchi, S. Brillanti
Journal: Journal of Hepatology (2016)
La rougeole en Europe en 2001-2002
Authors: M Muscat, S Glismann, H Bang
Journal: Eurosurveillance (2003)

Au total, 17 928 cas de rougeole ont ete declares en 2001-02 a EUVAC.NET, avec une augmentation de 41% des declarations entre ces deux annees, soit une incidence brute de 2,36 et 3,37 cas pour 100 000 en 2001 et 2002 respectivement. La majorite des cas declares etaient âges de 1 a 9 ans. En 2001, 18% des cas declares etaient associes a une epidemie, compares a 20% en 2002. Moins de 1% des cas etaient importes en 2001 et 2002. L'encephalite comme complication severe de la rougeole a ete rapportee dans 21 cas en 2001 et dans 6 cas en 2002. Un deces lie a la rougeole a ete rapporte en 2001. Le statut vaccinal etait connu pour 56% des cas declares en 2001 contre 72% en 2002. Dans l'ensemble, la proportion de cas declares de rougeole non vaccines est passee de 50% a 66% de 2001 a 2002.
A Photoreceptor Contributes to the Natural Variation of Diapause Induction in<i>Daphnia magna</i>
Authors: Anne C. Roulin, Yann Bourgeois, Urs Stiefel, Jean-Claude Walser, Dieter Ebert
Journal: Molecular Biology and Evolution (2016)

Diapause is an adaptation that allows organisms to survive harsh environmental conditions. In species occurring over broad habitat ranges, both the timing and the intensity of diapause induction can vary across populations, revealing patterns of local adaptation. Understanding the genetic architecture of this fitness-related trait would help clarify how populations adapt to their local environments. In the cyclical parthenogenetic crustacean Daphnia magna, diapause induction is a phenotypic plastic life history trait linked to sexual reproduction, as asexual females have the ability to switch to sexual reproduction and produce resting stages, their sole strategy for surviving habitat deterioration. We have previously shown that the induction of resting stage production correlates with changes in photoperiod that indicate the imminence of habitat deterioration and have identified a Quantitative Trait Locus (QTL) responsible for some of the variation in the induction of resting stages. Here, new data allows us to anchor the QTL to a large scaffold and then, using a combination of a new mapping panel, targeted association mapping and selection analysis in natural populations, to identify candidate genes within the QTL. Our results show that variation in a rhodopsin photoreceptor gene plays a significant role in the variation observed in resting stage induction. This finding provides a mechanistic explanation for the link between diapause and day-length perception that has been suggested in diverse arthropod taxa.
Encapsulation of SHT-DNA, siRNA and Polypeptide -17 inside Hybrid Polymeric Nano-Protein Folic Acid (HPNP-FA) Carrier as Targeted TGFb Inhibitor for Hepatocellular Carcinoma
Authors: N.A.N. Hanafy, A. Quarta, R. Di Corato, L. Dini, C. Nobile, M.L. De Giorgi, V. Tasco, S. Carallo, M. Cascione, R. Rinaldi, I. Fabregat, S. Leporatti
Journal: Journal of Hepatology (2016)
Access to Health Care
Authors: L. D. Wright
Journal: Annals of Internal Medicine (1993)

Letters1 February 1993Access to Health CareL. D. Wright, MDL. D. Wright, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-3-199302010-00026 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:All of us in the health care professions know we can't go on with “business as usual,” and it was refreshing to see the College step forward with a well conceived plan for America's health care.Having practiced in inner city emergency departments for almost 10 years, I suggest that the proposed copay to “discourage unnecessary services” be extended to all patients. One may certainly price-discriminate in a low-income patient's favor, but immediate access to the least cost-effective place to administer routine ambulatory care (for example, the emergency department) should have a cost to any person using ... Author, Article, and Disclosure InformationAuthors: L. D. Wright, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1993Volume 118, Issue 3Page: 232-235KeywordsAlcoholsEmergency departmentHealth care ePublished: 15 August 2000 Issue Published: 1 February 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Outcomes of Pure Laparoscopic versus Open Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients: A Case-Controlled Study with Propensity Score Matching
Authors: S. Tanaka, S. Takemura, G. Hamano, M. Kinoshita, T. Ito, S. Kubo
Journal: Journal of Hepatology (2016)
Case 28-2016
Authors: Richard S. Legro, Rocío M. Hurtado, Aoife Kilcoyne, Drucilla J. Roberts
Journal: New England Journal of Medicine (2016)

A 31-year-old Nepalese woman presented with primary infertility. Two cycles of in vitro fertilization had been unsuccessful. A hysterosalpingogram showed abnormal narrowing and outpouching of the distal fallopian tubes. Additional diagnostic procedures were performed.
Abstract P3-05-24: Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours
Authors: Damir Vareslija, Jean McBryan, Ailis Fagan, Aisling Redmond, Yuan Hao, Arnold DK Hill, Leonie S Young
Journal: Cancer Research (2015)

Abstract Acquired resistance to aromatase inhibitor therapy is a major clinical problem in the treatment of breast cancer. The detailed mechanisms of how tumour cells develop this resistance remain unclear. Here, discovery of pro-survival adaptations to the estrogen receptor (ER) signalling pathway in response to AI treatment is reported. Global ChIPseq analysis shows that the ER retains binding activity in AI resistant cells under steroid-depleted conditions. In AI treated patients, evidence of steroid independent adaptive ER signalling was demonstrated by the ER target gene Early Growth Response 3 (EGR3). Expression of EGR3 decreased initially upon AI treatment but subsequently recovered following as little as 12 weeks of AI treatment. In vitro data indicates that this increased expression of EGR3 may enhance cell growth and motility of tumour cells. Finally, evidence from established metastatic tumours suggests that the ER signalling network may undergo further adaptations with disease progression as EGR3 expression is routinely lost in the established metastatic tumour. Overall, these data provide evidence of a dynamic ER response to AI treatment which may provide vital clues for overcoming the clinical issue of AI resistance. Citation Format: Damir Vareslija, Jean McBryan, Ailis Fagan, Aisling Redmond, Yuan Hao, Arnold DK Hill, Leonie S Young. Adaptation to AI therapy in breast cancer can induce dynamic alterations in ER activity resulting in estrogen independent metastatic tumours [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-05-24.
Flow Cytometry: HD Flow Cytometry: An Improved Way to Quantify Cellular Interactions with Nanoparticles (Adv. Healthcare Mater. 18/2016)
Authors: Laura I. Selby, Nachnicha Kongkatigumjorn, Georgina K. Such, Angus P. R. Johnston
Journal: Advanced Healthcare Materials (2016)

Flow cytometry is used extensively to probe nanoparticle/cell interactions. However, distinguishing between weak nanoparticle fluorescence over cellular autofluorescence is challenging. L. Selby, A. Johnston and colleagues describe an algorithm that uses an iterative deconvolution process to identify the cells that have interacted with nanoparticles within the sample, allowing for the detection of small changes that would otherwise be missed, on page 2333.
Functional Variants and Aberrant Methylation in the SOCS3 Promoter Region Influence the Progression of HBV-Related Liver Diseases
Authors: N.X. Hoan, H. Van Tong, D.P. Giang, N.L. Toan, L.H. Song, C.-T. Bock, P.G. Kremsner, T.P. Velavan
Journal: Journal of Hepatology (2016)
Hsp72 Overexpression Protects from Liver Injury via Attenuation of Jnk Signalling
Authors: K. Levada, N. Guldiken, G. Vella, L.P. James, J. Haybaeck, A.K. Kiemer, S.M. Kessler, C. Trautwein, P. Strnad
Journal: Journal of Hepatology (2016)
MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
Authors: Jesùs F. San-Miguel, Katja C. Weisel, Philippe Moreau, Martha Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol Rocafiguera, Xin Yu, Lars Sternas, Christian Jacques, Mohamed H. Zaki, Meletios A. Dimopoulos
Journal: Journal of Clinical Oncology (2013)

8510 Background: RRMM patients (pts) who have exhausted treatment (Tx) with bortezomib (BORT) and lenalidomide (LEN) or thalidomide have a poor prognosis with short overall survival (OS). HiDEX is a well-established standard Tx in RRMM. POM has demonstrated clinical efficacy in pts refractory to LEN and BORT. MM-003 compared POM + LoDEX vs. HiDEX in RRMM pts who failed LEN and BORT and who progressed on their last Tx. Methods: Pts must have been refractory to last prior Tx (progressive disease [PD] during Tx or within 60 days) and failed LEN and BORT after ≥ 2 consecutive cycles of each (alone or in combination). Pts were randomized 2:1 to receive 28-day cycles of POM 4 mg D1–21 + DEX 40 mg (20 mg for pts aged &gt; 75 y) weekly or DEX 40 mg (20 mg for pts aged &gt; 75 y) D1–4, 9–12, and 17–20. Tx continued until PD or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included OS, overall response rate (ORR; ≥ partial response), and safety. Analyses were based on intent to treat. Results: 455 pts were randomized to POM + LoDEX (n = 302) or HiDEX (n = 153). The median number of prior Tx was 5 (range 1-17). 72% were refractory to LEN and BORT. Median follow-up was 4 months. POM + LoDEX significantly extended median PFS (3.6 vs. 1.8 months, HR = 0.45, P &lt; .001) and OS (not reached vs. 7.8 months, HR = 0.53, P &lt; .001) vs. HiDEX. The OS benefit was observed despite 29% of HiDEX pts receiving POM after PD. The trial met the primary endpoint of PFS, crossed the upper boundary for OS superiority, and the Data Monitoring Committee recommended crossover from HiDEX to POM ± DEX. With updated data, the ORR was 21% for POM + LoDEX vs. 3% for HiDEX (P &lt; .001) and 24% vs 3% for pts randomized ≥ 6 months post-enrollment (P &lt; .001). The most frequent grade 3/4 adverse events (AEs) for POM + LoDEX vs. HiDEX were neutropenia (42% vs. 15%), anemia (27% vs. 29%), and infection (24% vs. 23%). Discontinuation due to AEs was infrequent (7% vs. 6%). Updated data will be presented. Conclusions: POM + LoDEX significantly extended PFS and OS vs. HiDEX in pts who failed LEN and BORT. POM + LoDEX should become a standard of care in RRMM pts who have exhausted Tx with LEN and BORT. Clinical trial information: NCT01311687.
Angiographic Restenosis at 9 Months in the DIVERGE Trial, a Multi-Center Investigation of a Dedicated Drug-Eluting Bifurcation Lesion Stent
Authors: Alexandra J Lansky, Stefan Verheye, Christophe Dubois, Josef Dens, John Ormiston, Stephen Worthley, Ecaterina Cristea, Ovidiu Dressler, Martin Fahy, Lulian Benetato Giuran, Roxana Mehran
Journal: Journal of the American College of Cardiology (2009)
Immune-Escape Mutations and Stop-Codons in HBsAg Circulates in a Relevant Proportion of Patients with Chronic HBV Infection Exposed to Anti-HBV Drugs in Europe: Implications for HBV Transmission in the Setting of Vaccination and Disease Progression
Authors: L. Colagrossi, L.E. Hermans, R. Salpini, S.D. Pas, M. Alvarez, Z. Ben Ari, G. Boland, B. Bruzzone, N. Coppola, C. Seguin-Devaux, T. Dyda, F. Garcia, R. Kaiser, S. Köse, H. Krarup, I. Lazarevic, M.M. Lunar, S. Maylin, V. Micheli, O. Mor, S. Paraschiv, D. Paraskevis, M. Poljak, E. Puchhammer-Stöckl, F. Simon, M. Stanojevic, K. Stene-Johansen, N. Tihic, P. Trimoulet, J. Verheyen, A. Vince, N. Weis, T. Yalcinkaya, S.Z. Lepej, C.A. Boucher, A.M. Wensing, C.F. Perno, V. Svicher
Journal: Journal of Hepatology (2016)
Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Portal Hypertension with or without Portal Vein Thrombosis in 1,171 Patients with Cirrhosis: A 14-Year Retrospective Study from a Single Center
Authors: Y. Lv, B. Zhang, W. Guo, C. He, Z. Wang, Z. Yin, J. Wang, S. Ren, X. Meng, J. Cai, X. Qi, M. Bai, J. Niu, D. Fan, G. Han
Journal: Journal of Hepatology (2016)
Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities
Authors: Preetesh Jain, Hagop M. Kantarjian, Raja Luthra, Graciela Nogueras Gonzalez, Elias Jabbour, Koji Sasaki, Carlos Guillermo Romo, Keyur P. Patel, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2015)
Interventions against HCV &amp; HIV Infections among People who Inject Drugs (PWID) in Eastern Europe &amp; Central Asia: A Modeling and Cost-Effectiveness Study
Authors: G. Mabileau, I. Konorazov, M. Tsereteli, A. Yelizaryeva, S. Popovici, K. Saifuddin, E. Losina, M. Manova, V. Saldanha, J.-E. Malkin, Y. Yazdanpanah
Journal: Journal of Hepatology (2016)
CD26 Expression in Mature B-Cell Neoplasia: Its Possible Role as a New Prognostic Marker in B-CLL.
Authors: Lilla Cro, Nadia Zucal, Sonia Fabris, Antonino Neri, Marta Lionetti, Fortunato Morabito, Giovanna Cutrona, Manlio Ferrarini, Stefano Molica, Giorgio Lambertenghi Deliliers, Luca Baldini
Journal: Blood (2007)
Inhibition of VPAC1 Signaling Raises Platelet Numbers after Myelosuppressive Therapy and in GATA1 Congenital Thrombocytopenia.
Authors: Karen Peeters, Kathleen Freson, Christine Wittevrongel, Chantal Thys, Jean-Marie Stassen, Marc F. Hoylaerts, Chris Van Geet
Journal: Blood (2007)
Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS).
Authors: Haifu Li, Agnieszka Wozniak, Karel Van Den Bossche, Thomas Van Looy, Jasmien Wellens, Marguerite Stas, Giuseppe Floris, Lori Friedman, Maria Debiec-Rychter, Raf Sciot, Patrick Schoffski
Journal: Journal of Clinical Oncology (2013)

e13528 Background: Analysis of primary clinical specimens of DDLPS revealed evidence of AKT activation in 27% of cases (Gutierrez A, et al. Aberrant AKT activation drives well-differentiated liposarcoma. PNAS 2011; 108(39):16386-91). We evaluated the efficacy of the PI3K inhibitor GDC-0941 (GDC) alone and in combination with doxorubicin (DOX) in patient- and cell-line derived DDLPS xenografts with proven PI3K/AKT pathway activation. Methods: NMRI nu/nu mice were either injected bilaterally with 1x10 7 SW872 cells or transplanted with human DDLPS (UZLX-STS3). Animals were randomized to 4 groups (6 mice/group) and treated for two weeks: vehicle, DOX (i.p., 1.2mg/kg/biw), GDC (p.o., 75mg/kg/qd), GDC+DOX (same dose/schedule as single agents). Efficacy was assessed by tumor volume assessment, Western blotting and histological evaluation (H&amp;E). Mitotic and apoptotic effects were confirmed using immunostainings for phospho-histone H3 (p-H3) (for proliferation), and cleaved caspase 3 (CC3) (for apoptosis). Results: GDC and GDC+DOX significantly delayed the growth of both xenografts (74% decrease under GDC and 77% under GDC+DOX in SW872, 67% under GDC and 56% under GDC+DOX in UZLX-STS3, vs. control). GDC and GDC+DOX treatment resulted in reduced mitotic activity and increase in apoptosis, as compared to untreated tumors in both models (Table). The activation of PI3K signaling was nearly completely suppressed in the GDC and GDC+DOX treated groups in SW872, whilea weak activation of the pathway was still observed in UZLX-STS3. Conclusions: GDC-0941 has anti-tumor activity, decreases tumor proliferation and induces apoptosis in DDLPS with PI3K/AKT activation. The GDC+DOX combination did not show additive effect in vivo. [Table: see text]
Usutu virus infections in humans: a retrospective analysis in the municipality of Modena, Italy
Authors: A. Grottola, M. Marcacci, S. Tagliazucchi, W. Gennari, A. Di Gennaro, M. Orsini, F. Monaco, P. Marchegiano, V. Marini, M. Meacci, F. Rumpianesi, A. Lorusso, M. Pecorari, G. Savini
Journal: Clinical Microbiology and Infection (2016)
Neoadjuvant chemotherapy with XELOX regimen for locally advanced operable colon cancer patients: a prospective phase II trial (NCT02415829).
Authors: Li Yang, Fangqi Liu, Dan Huang, Junyan Xu, Lei Huang, Ye Xu
Journal: Journal of Clinical Oncology (2016)

e15047 Background: Several studies showed that the neoadjuvant chemotherapy (NAT) is an effective treatment of solid tumor malignancies. This study was a prospective, single-arm phase II trial to assess the efficacy and safety of XELOX regimen as neoadjuvant chemotherapy for locally advanced colon cancer patients. Methods: Patients with CT-defined T4 or lymph node-positive colon cancer were enrolled. After radiological staging, patients were treated with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score. The primary endpoints were tumor response rate. This trial is registered with ClinicalTrials.gov, number NCT02415829. Results: 46 patients were enrolled and received treatment. 5 patients were only received 1 cycle of NAC and excluded. 41 patients received at least 2 cycles of neoadjuvant chemotherapy and R0 resection. The total clinical response rate was 70.7% (29/41) including a complete response and partial response rate of 2.4% (1/41) and 68.3% (28/41), respectively. Stable disease was observed in 29.3% (12/41) of patients and no progressive disease in all patients. The total pathological response rate was based on TRG score. pCR(TRG0) , major regression(TRG1) and at least moderate regression(TRG2) were achieved in 1 (2.4%), 2 (4.9%), and 25 patients (61.0%), respectively. Grade 3/4 treatment toxicities were hematological toxicities and developed in 4 patients. Emergency operation conditions were observed in 3 patients with perforation or obstruction. Operation complications rate was 4.2% (1/46) with wound infection and mortality rate was 0. Conclusions: The results suggest that neoadjuvant chemotherapy with XELOX is an effective, feasible and safe treatment for patients with locally advanced colon cancer. Clinical trial information: 02415829.
Evolution and Determinants of the Prevalence of HCV Infection and Hcv Genotype Distribution among Hivinfected Patients Entering in Care between 1997–2015 in Italy: Data from a Prospective Nationwide Cohort (ICONA)
Authors: B. Rossetti, F. Bai, A. Tavelli, M. Galli, A. Antinori, F. Castelli, G. Pellizzer, A.C. Lepri, S. Bonora, A. d’Arminio Monforte, M. Puoti, A. De Luca
Journal: Journal of Hepatology (2016)
STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner
Authors: Lisa Schafranek, Eva Nievergall, Jason A. Powell, Devendra K. Hiwase, Deborah L. White, Timothy P. Hughes, Tamara Leclercq
Journal: Blood (2013)